Bryan Ardis — Benefits Deep Dive

Bryan Ardis’s public research divides into four threads, and they do not stand or fall together. The receptor-pharmacology layer (nicotinic acetylcholine receptors, the cholinergic anti-inflammatory pathway, the three-finger-toxin literature) rests on well-established neuroscience — Kevin Tracey’s inflammatory-reflex work in Nature, decades of elapid-toxin pharmacology, and the α-bungarotoxin and α-cobratoxin literature taught in every graduate neuroscience course. The protocol layer (transdermal nicotine, pine-needle tea, NAC, dandelion root, methylene blue) draws on a mix of traditional use, off-label practice, and preclinical or in-vitro data; almost none of it has been tested in a randomised trial at the doses people actually take. The structural-biology proposal — that the SARS-CoV-2 spike is in effect a synthetic venom peptide — is speculative, and its most publicised extension, the municipal-water-supply claim, does not survive scrutiny; the Snake Venom Hypothesis page states that plainly and sets out the mainstream rebuttals in full. The fourth thread, the documentary case against remdesivir and the early ventilator protocol, is the best-evidenced part of the body of work and the part the public argument has largely skipped over. Each card below opens an existing article on this site that maps one thread with the proponent argument and the mainstream response side by side, so the reader can form an independent judgment rather than being told what to conclude.

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. Why These Four Threads
3. Why There Is No Suramin Page
4. Research: Spike, 3FTx & the α7 Receptor
5. Research: Nicotine & the Cholinergic Anti-Inflammatory Pathway
6. Research: The Detox Stack
7. Research: The Hospital-Protocol Evidence Base
8. Research: Cross-Cutting — Origin, Endothelium & Open Questions
9. External Authoritative Resources
10. Connections
11. Featured Videos

Why These Four Threads

Of the dozens of topics Ardis has discussed on his podcast and in interviews, these four were selected for this hub because each one has an evidence base that can be evaluated on its own merits, separate from any other claim in his body of work. They are listed here in descending order of how well-supported they are — which is close to the reverse of the order in which they were publicised.

1. The hospital-protocol case is the best-documented thread. Every load-bearing figure in it comes from a mainstream journal: the failed remdesivir arm of the PALM Ebola trial in the New England Journal of Medicine, the ACTT-1 mortality readout whose confidence interval crossed unity, the WHO Solidarity trial finding no mortality benefit, and the 88% ventilated-patient mortality in the Northwell New York series in JAMA. What is debatable is the interpretation — whether the payment architecture explains the protocol, or merely coexisted with it. The underlying numbers are not in dispute.
2. Three-finger-toxin and nAChR pharmacology is a settled field with a fifty-year literature. The disulfide-stabilised fold, the receptor pharmacology, and the venom-evolution narrative are not controversial, and the human proteome contains its own three-finger-fold proteins (Lynx1, SLURP-1). What Ardis adds to that field — the claim that the SARS-CoV-2 spike is a deliberately engineered venom analog, delivered in part through municipal water — is a separate proposition that the established pharmacology does not carry. The spike’s high-affinity target is ACE2; its reported α7-nAChR affinity is far lower, which is the opposite of what an engineered nAChR-targeting peptide would look like. COVID also does not produce the clinical picture of elapid envenomation.
3. Nicotine as an α7-nAChR ligand is real pharmacology with an unfinished clinical file. The receptor exists, the cholinergic anti-inflammatory pathway is well described, and nicotine occupies the site. The observational smoking-prevalence signal has been analysed and re-analysed and remains confounded. What does not yet exist is an adequately powered randomised trial of transdermal nicotine in the relevant patient population at the relevant dose. That is the honest status: a plausible mechanism, a suggestive signal, and no proof of benefit. Nicotine is also addictive, raises heart rate and blood pressure, and is acutely dangerous to children and pets.
4. The detox stack is the weakest thread evidentially and the lowest-risk practically. Most of it is food-grade — NAC, vitamin C, zinc, quercetin, melatonin, dandelion, pine-needle tea. The supporting data are largely in-vitro or preclinical: an extract that blocks spike–ACE2 binding in a dish has not thereby been shown to help a patient. The safety case rests on long traditional use rather than on trials, and the specific hazards that do exist are botanical rather than pharmacological — misidentifying a yew for a pine, or drinking pine-needle tea in pregnancy.

Back to Table of Contents

Why There Is No Suramin Page

An earlier draft of this hub advertised a page on “suramin and pine-needle tea.” That page was never written, and it should not be, because the claim that joins the two halves of its title is not chemically possible.

• Suramin is a wholly synthetic molecule. It is a symmetrical polysulfonated naphthylurea first prepared at Bayer in 1916 and marketed as Bayer 205 / Germanin. It has no natural source. It is not extracted from a plant, and no plant makes it or anything that converts into it.
• Pine needles contain shikimic acid, which is a different compound entirely. Shikimic acid is a small cyclohexene carboxylic acid. Its industrial claim to fame is as the starting material for the chemical synthesis of oseltamivir (Tamiflu) — a multi-step synthesis performed in a factory. Shikimic acid is not suramin, is not a precursor of suramin, and is not oseltamivir either. Drinking pine-needle tea delivers shikimic acid and assorted phenolics; it does not deliver suramin, and it does not deliver Tamiflu.
• Suramin is also not an oral drug. It carries six sulfonate groups, is highly charged, and is given by slow intravenous injection. Its recognised uses are parasitic: early-stage African trypanosomiasis and onchocerciasis. Its toxicity profile includes nephrotoxicity, peripheral neuropathy and adrenal insufficiency. It is not a supplement and is not self-administrable.
• Suramin does have a genuine research literature — as a broad purinergic (P2X/P2Y) receptor antagonist, which is the basis of the antipurinergic-therapy work in autism reviewed by Naviaux (cited below). That literature is real and is worth reading. It has nothing to do with pine needles.

Pine-needle tea is covered honestly on the Detox & Recovery page on its own modest merits, and pine as a botanical is covered on Pine Needle Oil. Neither page claims it is a source of suramin, because it is not.

Back to Table of Contents

Research Papers: Spike, Three-Finger Toxins & the α7 Receptor

These are the primary papers behind the receptor-homology argument. Note what they are and are not: they are structural-biology and in-silico docking studies proposing an interaction, plus one cell-level follow-up. None of them claims the spike was engineered, and none of them says anything about water supplies.

1. Changeux JP, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. C R Biol. 2020;343(1):33-39. PMID 32720486
2. Lagoumintzis G, Chasapis CT, Alexandris N, et al. Nicotinic cholinergic system and COVID-19: in silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV and SARS-CoV-2 spike glycoproteins. Food Chem Toxicol. 2021;149:112009. PMID 33503469
3. Oliveira ASF, Ibarra AA, Bermudez I, et al. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. Biophys J. 2021;120(6):983-993. PMID 33609494
4. Tanmay S, Labrou D, Farsalinos K, Poulas K. Is SARS-CoV-2 spike glycoprotein impairing macrophage function via α7-nicotinic acetylcholine receptors? Food Chem Toxicol. 2021;152:112184. PMID 33838172
5. Alexandris N, Lagoumintzis G, Chasapis CT, et al. Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions. Toxicol Rep. 2021;8:73-83. PMID 33425684

For the underlying toxin literature, which is far too large to list, search it directly:

1. PubMed: Three-finger toxins — structure, function, evolution
2. PubMed: α-Bungarotoxin and nAChR binding
3. PubMed: Lynx1 / SLURP-1 — the human three-finger-fold proteins
4. PubMed: Spike–ACE2 binding affinity

Back to Table of Contents

Research Papers: Nicotine & the Cholinergic Anti-Inflammatory Pathway

The mechanism papers are strong; the clinical papers are observational. Both are listed, and the difference between them is the whole argument.

1. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-859. PMID 12490958 — the foundational description of vagal cholinergic control of inflammation.
2. Barrantes FJ. Structure and function meet at the nicotinic acetylcholine receptor-lipid interface. Pharmacol Res. 2023;190:106729. PMID 36931540
3. Farsalinos K, Bagos PG, Giannouchos T, et al. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J. 2021;18(1):9. PMID 33453726 — a re-analysis, not a trial; the authors themselves treat the finding as hypothesis-generating.
4. Leitzke M. Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? Bioelectron Med. 2023;9(1):2. PMID 36650574 — a hypothesis paper with case observations, not controlled evidence.

1. PubMed: Cholinergic anti-inflammatory pathway
2. PubMed: Transdermal nicotine — pharmacokinetics and safety
3. PubMed: Nicotine randomised trials in COVID-19
4. PubMed: Smoking and COVID-19 — confounding and bias

Back to Table of Contents

Research Papers: The Detox Stack

Read these for what they measured. Two are analytical-chemistry papers establishing that conifer needles contain shikimic acid; one is a cell-free binding assay; one is a proteomics study of microclots. None is a clinical trial of a detox protocol.

1. Bai J, Wu Y, Liu X, et al. Antibacterial activity of shikimic acid from pine needles of Cedrus deodara against Staphylococcus aureus through damage to cell membrane. Int J Mol Sci. 2015;16(11):27145-27155. PMID 26580596
2. Chen F, Hou K, Li S, et al. Extraction and chromatographic determination of shikimic acid in Chinese conifer needles with 1-benzyl-3-methylimidazolium bromide ionic liquid aqueous solutions. J Anal Methods Chem. 2014;2014:256473. PMID 24782942
3. Tran HTT, Gigl M, Le NPK, et al. In vitro effect of Taraxacum officinale leaf aqueous extract on the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614 and four mutants. Pharmaceuticals (Basel). 2021;14(10):1055. PMID 34681279 — the dandelion paper. It is an in-vitro binding study; no patient was treated.
4. Kruger A, Vlok M, Turner S, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190. PMID 36131342
5. Naviaux RK. Antipurinergic therapy for autism — an in-depth review. Mitochondrion. 2018;43:1-15. PMID 29253638 — the real suramin research literature, included so readers can see what it actually says.

1. PubMed: NAC, glutathione and COVID-19 outcomes
2. PubMed: Nattokinase / serrapeptase and fibrinolysis
3. PubMed: Suramin as a purinergic receptor antagonist
4. PubMed: Pine-needle toxicity and abortifacient effects

Back to Table of Contents

Research Papers: The Hospital-Protocol Evidence Base

Every one of these is a mainstream trial or case series published in a first-tier journal. This is the part of the Ardis case that rests entirely on the medical literature’s own record of itself.

1. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303. PMID 31774950 — the PALM trial, in which the remdesivir arm performed worst.
2. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813-1826. PMID 32445440 — ACTT-1: faster recovery, mortality difference not statistically significant.
3. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941-1953. PMID 35512728
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. PMID 32320003 — the Northwell series behind the widely quoted ventilated-patient mortality figure.

1. PubMed: Remdesivir and the acute-kidney-injury signal
2. PubMed: Ventilator mortality in the first COVID wave
3. PubMed: COVID ARDS phenotypes and ventilation strategy

Back to Table of Contents

Research Papers: Cross-Cutting — Origin, Endothelium & Open Questions

Two papers sit across all four threads. The first is the strongest single obstacle to the engineered-origin claim; the second supports the vascular reading of COVID pathology that the receptor argument depends on. A reader who wants to test the Ardis case against itself should start with both.

1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-452. PMID 32284615 — the phylogenetic argument against deliberate construction. Its own conclusions have since been debated at length, and readers should follow that debate rather than treat the paper as final.
2. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128. PMID 32437596 — autopsy evidence that severe COVID is substantially a vascular and endothelial disease.

What would actually settle the open questions. The receptor thread would be settled by a direct binding-affinity measurement of spike against α7-nAChR and by an adequately powered randomised trial of transdermal nicotine at a defined dose in a defined population. The detox thread would be settled by clinical endpoints rather than in-vitro binding assays. The engineered-origin thread turns on evidence about laboratory records rather than on pharmacology, and no amount of structural biology will resolve it either way. Naming which evidence would change one’s mind is the difference between a hypothesis and a position.

1. PubMed: SARS-CoV-2 origins — the continuing literature
2. PubMed: Long COVID, endothelial dysfunction and microclots
3. PubMed: Anything indexed under Bryan Ardis — run it yourself and see what comes back.

Back to Table of Contents

External Authoritative Resources

• PubMed (NLM) — the primary index. Every citation on this page carries its PMID so it can be checked in one click.
• ClinicalTrials.gov — where to check whether a proposed therapy has actually been trialled, and what its registered endpoints were before the results came in.
• WHO therapeutics guidance for COVID-19 — the living guideline that carries the recommendation on remdesivir use.
• WHO fact sheet: human African trypanosomiasis — the actual clinical setting in which suramin is used.
• LiverTox (NIDDK/NLM) — NIH reference on drug and supplement hepatotoxicity, useful before adding anything to a stack.
• NIH Office of Dietary Supplements — fact sheets on the vitamin and mineral components of the detox stack.
• Poison Help (HRSA) — 1-800-222-1222. Relevant because nicotine patches and concentrated nicotine are a genuine paediatric and veterinary poisoning hazard.

Back to Table of Contents

Connections

• Dr. Bryan Ardis: The Nicotine Hypothesis, COVID Lies & the Snake-Venom Theory — the parent hub this Benefits section expands on.
• The Synthetic-Venom-Peptide Hypothesis — the three-finger-toxin thread in full, with the mainstream rebuttals.
• Nicotinic Acetylcholine Receptors (nAChRs) — the established receptor pharmacology the nicotine thread rests on.
• Nicotine Patch Protocol — dosing, sourcing, tapering, and contraindications for the transdermal protocol.
• The Nicotine Hypothesis — nicotine decoupled from combustion, and what the observational data can and cannot show.
• Detox & Recovery — the spike-clearance stack agent by agent, including pine-needle tea and shikimic acid.
• Hospital Protocols and Remdesivir — the trial record, the AKI signal, and the ventilator-mortality data.
• COVID Lies, Chapter by Chapter — the book itself, its reception, and how to read it critically.
• Vaccine-Injury Recovery — the post-vaccination symptom protocol and what supports it.
• Tobacco, Indigenous Medicine & Therapeutic Nicotine — the 60-year history behind the nicotine thread.
• Bryan Ardis: History and Origins — how a chiropractor came to be at the centre of this argument.
• Pine Needle Oil — what pine actually contains, and what it does not.
• Remedies — the category landing page for practitioners, protocols, and practices.

Back to Table of Contents

Featured Videos

×